Activity of once-daily cefpodoxime regimens against Haemophilus influenzae and Streptococcus pneumoniae with an in vitro pharmacodynamic chamber model

To characterize the in vitro effectiveness of once-daily dosing with cefpodoxime against Haemophilus influenzae and Streptococcus pneumoniae infections, an in vitro pharmacodynamic chamber model was used to compare the bacterial killing activities of three cefpodoxime regimens: 100 mg twice daily (BID), 200 mg once daily (QD), and 400 mg QD. At the end of 24 h, the regrowth of H. influenzae isolates in the QD regimens was of concern, and the total logarithmic reduction was greatest in the BID regimen (3.1 log). Against S. pneumoniae isolates, the largest reductions in bacterial counts were observed in the 100-mg BID (5.5 log) and 400-mg QD (4.0 log) regimens. These data suggest that 400 mg of cefpodoxime given QD may have a role in the therapy of infections involving S. pneumoniae isolates.